Skip to main content
Top

Familial Cancer

Issue 2/2006

Breast Cancer Treatment and Genetics

Content (15 Articles)

Interleukin-10 Polymorphisms, Cancer Susceptibility and Prognosis

W. Martin Howell, Matthew J. Rose-Zerilli

Determinants of Preferences for Genetic Counselling in Jewish Women

Carmel Apicella, Stuart J. Peacock, Lesley Andrews, Katherine Tucker, Agnes Bankier, Mary B. Daly, John L. Hopper

Late-Onset Common Cancers in a Kindred with an Arg213Gln TP53 Germline Mutation

Mariëlle W. G. Ruijs, Senno Verhoef, Gea Wigbout, Roelof Pruntel, Arno N. Floore, Daphne de Jong, Laura J. van ′t Veer, Fred H. Menko

Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families

Kirsi Pylvänäinen, Matti Kairaluoma, Jukka-Pekka Mecklin

Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients

M. Spaepen, B. Vankeirsbilck, S. Van Opstal, S. Tejpar, E. Van Cutsem, K. Geboes, E. Legius, G. Matthijs

Desmoid Tumors – a Characterization of Patients Seen at Mayo Clinic 1976–1999

Taya Fallen, Marcia Wilson, Bruce Morlan, Noralane M Lindor

A Novel Exon Duplication Event Leading to a Truncating Germ-line Mutation of the APC Gene in a Familial Adenomatous Polyposis Family

Amy McCart, Andrew Latchford, Emmanouil Volikos, Andrew Rowan, Ian Tomlinson, Andrew Silver

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine